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Abstract 
Objective 
Factorial designs can allow efficient evaluation of multiple treatments within a single trial. We 
evaluated the design, analysis, and reporting in a sample of factorial trials.  
 
Study design and setting 
Review of 2x2 factorial trials evaluating health-related interventions and outcomes in humans. Using 
MEDLINE, we identified articles published between January 2015 and March 2018. We randomly 
selected 100 articles for inclusion.  
 
Results 
Few trials (22%) provided a rationale for using a factorial design. Only 63 trials (63%) assessed the 
interaction for the primary outcome, and 39/63 (62%) made a further assessment for at least one 
secondary outcome. 12/63 trials (19%) identified a significant interaction for the primary outcome, 
and 16/39 trials (41%) for at least one secondary outcome. Inappropriate methods of analysis to 
protect against potential negative effects from interactions were common, with 18 trials (18%) 
choosing the analysis method based on a preliminary test for interaction, and 13% (n=10/75) of 
those conducting a factorial analysis including an interaction term in the model. 
 
Conclusions 
Reporting of factorial trials was often suboptimal, and assessment of interactions was poor. 
Investigators often used inappropriate methods of analysis to try to protect against adverse effects 
of interactions.  
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What is new 
Key findings 
• Interactions were common, with 12/63 trials (19%) identifying a significant interaction for 
the primary outcome, and 16/39 trials (41%) for at least one secondary outcome. 
• Evaluation of interactions was often suboptimal, with only 63 trials (63%) assessing the 
interaction for the primary outcome, and 39/63 (62%) for at least one secondary outcome 
• Few trials evaluated the size of the interaction or provided a measure of uncertainty 
 
What this adds to what is known 
• Investigators often used inappropriate methods of analysis to protect against potential 
interactions, with 18% of trials choosing the analysis method based on a preliminary test 
for interaction, and 13% (n=10/75) of those conducting a factorial analysis including an 
interaction term in the model 
 
What is the implication, what should change now 
• Improvement in the analysis and reporting of factorial trials is required to allow valid 
conclusions to be drawn when this design is used 
  
Introduction 
Factorial trials allow investigators to assess multiple interventions within a single trial without 
increasing the sample size, provided the treatments work independently [1-3]. For example, the ISIS-
2 trial [4] allocated 17,187 patients with suspected acute myocardial infarction to streptokinase, 
aspirin, both streptokinase and aspirin, or double-placebo. Streptokinase and aspirin were thought 
to work through different mechanisms (with aspirin preventing clots, and streptokinase dissolving 
clots). The investigators conducted a ‘factorial’ (or ‘at the margins’) analysis, which compared all 
patients allocated to streptokinase (streptokinase alone + streptokinase and aspirin) vs. all those not 
allocated to streptokinase (aspirin alone + double-placebo), and a similar analysis was conducted for 
aspirin. They found that streptokinase and aspirin independently reduced 5-week vascular mortality. 
Assessing these interventions in separate trials of the same sample size likely would have been 
unfeasible.  
 
The factorial analysis used in the ISIS-2 trial assumes that there is no interaction between 
treatments. In other words, the effect of aspirin is the same regardless of whether the patient also 
received streptokinase, and vice versa. When treatments do interact, results from a factorial analysis 
can be misleading [1-3, 5-10]. When treatments are known to interact, a ‘multi-arm’ (or ‘inside-the-
table’) analysis is more appropriate (table 1). For example, in ISIS-2, this would involve separately 
comparing each of the three active treatment groups (streptokinase alone, aspirin alone, and 
streptokinase + aspirin) against double-placebo. This analysis is valid even when treatments interact, 
however it requires a larger overall sample size to achieve the same power as a factorial analysis.    
 
When efficiency is the main aim, it is generally recommended that factorial trials are undertaken 
only when no interaction is expected (for instance, if treatments are expected to work through 
different mechanisms or target different endpoints). However, it is often difficult to rule out 
interactions entirely at the design stage, and so if a factorial analysis is used, some assessment of the 
interaction between treatments is warranted. This could involve assessing the magnitude of the 
interaction effect (along with a measure of uncertainty, such as a confidence interval), and 
conducting a multi-arm analysis as a sensitivity analysis to evaluate to what extent results from the 
factorial analysis may be affected by an interaction. However, previous research has shown that this 
is infrequently done [1, 2, 5]. Furthermore, investigators may sometimes use inappropriate analytical 
methods in an attempt to guard against the adverse consequences of an interaction, such as 
choosing the method of analysis based on results from an interaction test [6], or conducting a 
factorial analysis which includes a term for the interaction between treatments in the model (table 
2). 
 
We conducted a review of recently published factorial trials to evaluate whether the design, 
analysis, and reporting of trials was appropriate, and to identify the prevalence of reported 
interaction.  
 
 
 
 
 
  
Methods 
Data source and search methods 
We searched Medline from inception to March 31st, 2018 (search performed April 2018) for 
published reports of randomised trials utilising a factorial design. The full search strategy is available 
in the supplementary file. One author then screened titles and abstracts to assess eligibility. 
Subsequently the full text was assessed for eligibility by two reviewers. The full eligibility criteria are 
available in the supplementary file. Briefly, articles were eligible if they were the main trial 
publication from a 2x2 factorial trial conducted in humans with health-related interventions and 
outcomes, published between January 2015 and March 2018 inclusive. We excluded trials with 
health economic outcomes only, laboratory or in vitro studies, dose response or dose finding 
studies, trials employing a crossover or N-of-1 design, educational interventions or interventions 
aimed at health practitioners rather than patients, studies where factors were not randomly 
allocated, or letters or commentaries/editorials.  
 
After eligibility screening, we randomly selected 100 trials from the final set of eligible trials for data 
extraction. This was done by using a random number generator to sort eligible articles into a random 
order and selecting the first 100 articles. We specified this number (n=100) prior to conducting the 
search, as this sample size was likely to enable us to identify any major deficiencies around the 
design, analysis, or reporting.  
 
 
Data extraction 
All articles were extracted independently by two separate authors onto a pre-piloted data extraction 
form, and discrepancies were resolved by discussion. When discrepancies could not be resolved, a 
third author acted as arbitrator. During the data extraction period, we updated the data extraction 
form twice, either to clarify questions or to add additional options for certain questions. When 
necessary, we went back and updated previously extracted results to ensure they were consistent 
with the updated form. The final version of the data extraction form is available in the 
supplementary file.  
 
We extracted information on the design, analysis, and reporting aspects specific to factorial trials. 
These included the rationale for utilising a factorial design, whether separate primary outcomes 
were specified for each factor, analysis approach used for the sample size calculation, randomisation 
approach, description of blinding, patient flow, method of statistical analysis, assessment of 
interactions, and reporting of descriptive statistics. Some data extraction items related to the 
primary outcome. We pre-specified the following strategy to identify a single primary outcome for 
extraction: (1) if only one outcome was listed as being primary, we used this; (2) if either no 
outcomes or multiple outcomes were listed as being primary, we used the outcome that was used in 
the sample size calculation; and (3) if no sample size calculation was performed, we used the first 
clinical outcome listed in the Objectives or Outcomes section of the article, or the first clinical 
outcome listed in the Results section of the article if there was no Objectives/Outcomes section.  
 
We assessed additional online supplementary material only when this was specifically referred to 
within the main text as containing additional information on the item in question. We did not refer 
to other published papers (e.g. published protocols, secondary papers), as we wished to evaluate 
reporting of the paper as a standalone item.  
 
We summarised results descriptively. All analyses were conducted using Stata v15.1.  
  
Results 
Our initial search found 3200 citations (figure 1). After removing duplicates and those not meeting 
the inclusion/exclusion criteria, 122 eligible articles remained. We randomly selected 100 of these 
for inclusion in this review. Two of the selected articles reported results for different factors from 
the same trial; we included these in the review as two separate articles, and evaluated reporting in 
each based on the standalone article. Design characteristics of trials are provided in table 3.  
 
 
Quality of reporting 
Quality of reporting is shown in table S1. Only 22% of trials (22/100) provided an explicit rationale 
for why they chose to use a factorial design. Only 25% of trials (25/100) reported the number of 
patients allocated to each factorial group, although 84% (84/100) did report the number allocated to 
each multi-arm group. 
 
Over a quarter of trials (28%, 20/71) did not make clear whether their sample size calculation was 
based on a factorial or multi-arm analysis approach. The analysis approach was generally well 
reported, however of the 75 trials using a factorial analysis, 9 (12%) did not report whether they 
adjusted for the other factor in the analysis, and 21 (28%) did not report sufficient detail to allow 
readers to judge whether investigators included an interaction term in the analysis.  
 
In the abstract, 24% of trials (24/100) did not report whether results were based on a factorial or 
multi-arm analysis, and 14% of trials (14/100) reported a treatment effect for only one of the two 
factors.  
 
 
Assessment of interaction 
The presence of interactions was poorly reported for the primary outcome (table 4); 37% of trials 
(37/100) made no mention of interactions, and most trials provided only a p-value or simply stated 
whether an interaction was present or not. Only 12% of trials (12/100) presented an estimate of the 
size of the interaction, with only 3% (3/100) providing a confidence interval for the estimate. 
Interactions for the primary outcome were also poorly reported in abstracts, with only 22% of trials 
(22/100) discussing interactions (11 trials provided a p-value, 11 stated whether an interaction was 
present). Of the trials which made an assessment of the interaction for the primary outcome, 39/63 
(62%) further assessed the presence of interactions for secondary outcomes.   
 
Of those trials reporting interactions, almost one fifth (n=12/63, 19%) found a statistically significant 
interaction for the primary outcome (at the 5% level), and 41% (n=16/39) found a significant 
interaction for at least one secondary outcome. In 33% of trials (n=13/39) there was an 
inconsistency between the primary and secondary outcomes in terms of whether a statistically 
significant interaction was observed (i.e. a significant interaction was observed for the primary 
outcome but not for all secondary outcomes, or vice versa).  
 
Additional subgroup results are available in tables S4-S6 in the supplementary material. 
 
Analysis of primary outcome 
Most trials (51%, 51/100) used a factorial analysis as their primary analysis approach, and 23% 
(23/100) used a multi-arm analysis (table 5). Only 26% of trials (26/100) presented analysis results 
from both a factorial and multi-arm analysis to allow comparison between the two approaches. 
Most trials presented descriptive statistics of the primary outcome by multi-arm groups only (38%, 
38/100), with 19% (19/100) presenting only by factorial groups, and 27% (27/100) presenting for 
both multi-arm and factorial groups (table S3).  
 
A number of trials used inappropriate methods of analysis to guard against the effects of an 
interaction; 18% of trials (18/100) chose their primary method of analysis on the basis of an 
interaction test, thereby introducing bias into the results. Furthermore, 13% of trials (10/75) which 
used a factorial analysis did so by including an interaction term in the model, thereby inadvertently 
reducing the sample size for each comparison by 50%, which may have led to an underpowered 
analysis.   
 
 
 
  
Discussion 
In this review of 100 articles reporting results from factorial trials, we found that reporting was often 
inadequate, making it difficult to ascertain the validity of results. For instance, few trials explicitly 
reported why they had chosen a factorial design, and in over a quarter of cases it was not clear 
which analysis approach the sample size calculation was based on. Most notably, assessment of 
interactions was poor. We found that 37% of trials (37/100) did not assess the presence of an 
interaction for their primary outcome. Those that did assess the interaction often did so poorly, by 
only presenting a p-value, or stating whether the interaction was significant. This approach is 
problematic, as trials are typically underpowered to detect clinically relevant interactions, and so 
this approach may falsely reassure investigators that results are robust. A preferable approach 
would be to present the size of the estimated interaction along with a measure of uncertainty, such 
as a confidence interval. Furthermore, we found that most trials that used a factorial analysis did not 
also present results from a multi-arm analysis to allow comparison between the two.  
 
Many trials assessed the interaction for the primary outcome, but not for any secondary outcomes. 
This may be based on the mistaken belief that interactions amongst secondary outcomes are less 
important. However, this is incorrect, as interactions amongst secondary outcomes have the same 
implications for bias. Alternatively, investigators may believe that ruling out an interaction for the 
primary outcome means it is ruled out for the entire trial. We found this was generally not the case; 
for many trials, treatments were found to interact for some, but not all, outcomes. In practice, there 
may often be scientific reasons why treatments are more likely to interact for some outcomes but 
not others (e.g. to interact for efficacy outcomes but not safety outcomes, or vice versa).This 
highlights the need to assess interactions and perform appropriate sensitivity analyses for all 
outcomes, rather than solely for the primary outcome.  
 
Statistically significant interactions were relatively common, with 19% of trials (12/63) reporting a 
significant interaction for their primary outcome, and 41% of trials (16/39) reporting a significant 
interaction for at least one secondary outcome. These results may be in part driven by multiplicity, 
as the more interactions that are reported, the more likely that some will be statistically significant 
just by chance. Furthermore, some of the reported interactions may have been statistical 
interactions based on the chosen analysis scale, rather than true biological interactions. For instance, 
an interaction may be observed on the risk difference scale even if treatment effects are constant on 
the risk ratio scale. However, these interactions still pose challenges in the analysis and 
interpretation of such trials, regardless of whether they are true biological interactions.  
 
We found that investigators often used inappropriate methods to try to account for possible 
interactions. Almost a fifth of trials chose their method of analysis based on the results of a 
preliminary test for interaction. This figure may however be an underestimate, as it is possible that 
some trials used this approach without explicitly reporting it. This approach introduces bias into 
estimated treatment effects, and should not be used [6]. Furthermore, 13% of trials (10/75) included 
an interaction term in the model when implementing a factorial analysis. This approach 
inadvertently excludes 50% of the sample size from each comparison, and thus loses all the 
efficiency benefits from a factorial design. There are different approaches to dealing with potential 
interactions when a factorial design has been chosen for efficiency based on an a priori assumption 
of no interaction. Our preferred approach would be to evaluate the likely size of interaction through 
its estimated effect and 95% confidence interval, and, alongside the factorial analysis, to also include 
results from a multi-arm analysis (which does not depend on assumptions about no interaction) to 
allow comparison between the two analysis approaches. Sensitivity analyses which to evaluate to 
what extent conclusions from a factorial analysis may be affected under different plausible 
assumptions about the size of the interaction could also be useful [11, 12].  
 
The issues surrounding the design, analysis, and reporting often made it difficult to determine 
whether appropriate methods had been used, and whether results were at risk of bias. Guidance for 
reporting results from clinical trials are available in the CONSORT statement [13], with extensions 
available for several unique trial designs, such as cluster [14], non-inferiority [15], pragmatic [16], N-
of-1 [17], pilot and feasibility [18], and within person trials [19]. Given the unique features of 
factorial trials, reporting guidelines for such designs are warranted.  
 
Our results are similar to earlier evaluations of factorial trials, indicating that reporting has not 
improved over time [1, 2, 5]. McAlister et al [1] reviewed 44 trials with clinically important binary 
outcomes, with most trials (66%) being myocardial ischemia trials; Montgomery et al [2] reviewed 
76 trials which evaluated complex interventions in community settings; and Freidlin and Korn [5] 
reviewed 30 oncology trials. The main area of difference was that McAlister et al found only 6% of 
interactions were statistically significant, which is substantially lower than the 19% we found for 
primary outcomes.  This discrepancy may be in part due to the differences between samples, as we 
included trials regardless of outcome type or clinical area; it is possible that treatments used in 
myocardial ischemia trials or with clinically important binary outcomes are less likely to interact. Of 
note, our results are in line with those from Freidlin and Korn, who found 17% of trials in their 
review reported an interaction.  
 
There were some limitations to our review. Only one author screened titles and abstracts for 
eligibility, and so some eligible articles may have erroneously been excluded. We only included trials 
published in journals indexed in Medline; trials published in other journals may be reported and 
conducted differently. It is likely that had we restricted our search to high impact-factor journals, our 
results might have shown better reporting. However, this is not guaranteed; some high impact-
factor journals have policies of publishing separate articles for each factor (i.e. one article describing 
results for treatment A, and a separate article for treatment B), which typically leads to poor 
reporting of many aspects, notably around the interaction. Our review only included 2x2 factorial 
trials; higher order designs have additional issues. Finally, poor reporting in many articles made it 
difficult to assess whether appropriate methods had been used.  
 
Conclusions 
In this review of published 2x2 factorial trials, reporting around many aspects was inadequate, and 
often meant that it was impossible to assess whether main results were valid. Interactions were 
relatively common, and many trials did not appropriately assess whether interactions may have 
affected the validity of their results. Furthermore, many trials used inappropriate analysis methods 
to attempt to combat the effects of interactions.  
  
Figure 1: Flow diagram of factorial trials  
 
 
  
Table 1: Hypothetical 2x2 factorial trial 
  Treatment B  Margin 
  Yes No  
Treatment A Yes Both A and B 
 
(multi-arm group: 
both A and B) 
A alone 
 
(multi-arm group: 
A alone) 
All A  
 
(factorial group: treatment 
A) 
 No B alone 
 
(multi-arm group: B 
alone) 
Neither A nor B 
 
(multi-arm group: 
double-control) 
All non-A 
 
(factorial group: control A)  
Margin  All B 
 
(factorial group: 
treatment B) 
All non-B 
 
(factorial group: 
control B) 
   
 
 
Table 2: Potential pitfalls in the analysis of factorial trials 
Problem Explanation 
Inadequate assessment of 
interaction 
Factorial analyses can be misleading when treatments interact; 
therefore, evaluation of the interaction is important to assess 
whether results from a factorial analysis are likely to be valid 
[1-3, 6]. Often interactions are assessed using a significance 
test, with a p-value > 0.05 indicating there is no interaction. 
This approach is problematic, as this test has very low power to 
detect true interactions, and so will usually give false 
reassurance. A preferable approach is to present the size of the 
interaction term with a measure of uncertainty (for instance, a 
95% confidence interval). 
Choosing the final analysis 
approach (factorial vs. multi-
arm) based on a test for 
interaction (two-stage 
approach.  
This approach involves performing a preliminary test for 
interaction. If the interaction is not statistically significant, a 
factorial analysis is used; if it is significant, a multi-arm analysis 
is used. This approach is not advisable, as it introduces bias into 
estimated treatment effects [6]. This bias occurs for two 
reasons. First, the preliminary test has low power to detect 
interactions, and so often leads to factorial analyses even for 
moderate or large interactions. Second, the interaction test is 
correlated with the size of treatment estimates from a multi-
arm analysis, meaning that using these estimates only when 
the test is significant will lead to estimates that are too large 
[6]. 
Adjustment for the interaction 
term in the model when 
conducting a factorial analysis 
It is unclear what the rationale behind this approach is, but it 
may be to try and maintain the efficiency of a factorial analysis 
whilst accounting for potential interactions. However, this 
approach is flawed, as it does not maintain efficiency. It is in 
fact identical to a multi-arm analysis using different 
parametrisation, and so involves inadvertently discarding 50% 
of the sample size from each comparison, leading to 
substantial losses in power and precision. 
 
 
Table 3 – Design characteristics 
 Trials (n=100) 
Rationale for using factorial design  
Rationale stated for using factorial design 22 (22) 
Rationale   
     Efficiency 3 
     Assess presence of interaction 10 
     Both efficiency and interaction 3 
     Other 3 
     Unclear 3 
Stated why no interaction expected (trials where efficiency was only aim) 0/3 
Sample size  
Sample size calculation reported  
     No* 29 (29) 
     Yes 71 (71) 
Sample size calculation based on:  
     Factorial analysis 30/71 (42) 
     Multi-arm analysis 21/71 (30) 
     Unclear 20/71 (28) 
Interaction assumed in sample size calculation  
     Yes 5/71 (7) 
     No 58/71 (82) 
     Unclear 8/71 (11) 
Randomisation  
Randomisation approach  
     Combination of factors 84 (84) 
     Separate factors 5 (5) 
     Unclear 11 (11) 
Randomisation to different factors done all at once  
     Yes 81 (81) 
     No 7 (7) 
     Unclear 12 (12) 
All participants randomised to all factors  
     Yes 88 (88) 
     No 8 (8) 
     Unclear 4 (4) 
Blinding  
Description of blinding  
     Described separately for each factor 32 (32) 
     Described generally, but not specific to each factor 48 (48) 
     Blinding not mentioned 19 (19) 
     Unclear 1 (1) 
*No sample size calculation reported (n=23), article stated no sample size calculation performed 
(n=6) 
 
  
Table 4 – Assessment of interaction 
 Trials (n=100) 
Interaction assessment in the main text  
Any interaction results presented for primary outcome?  
     No 37 (37) 
     Yes 63 (63) 
Reported effect size of interaction 12 (12) 
Reported confidence interval for effect size of interaction 3 (3) 
Reported p-value for interaction 44 (44) 
Made statement that there was/was not an interaction present, but 
presented no other information 
18 (18) 
Any interaction results presented for any secondary outcomes?*  
     No 61/63 (38) 
     Yes 39/63 (62) 
Interaction assessment in the abstract  
Any interaction results presented for primary outcome?  
     No 78 (78) 
     Yes 22 (22) 
Reported effect size of interaction 0 (0) 
Reported confidence interval for effect size of interaction 0 (0) 
Reported p-value for interaction 11 (11) 
Made statement that there was/was not an interaction present, but 
presented no other information 
11 (11) 
Statistical significance of interactions  
Interaction for primary outcome statistically significant at 5% level* 12/63 (19) 
Interaction for at least one secondary outcome statistically significant at 5% 
level** 
16/39 (41) 
Discrepancy in statistical significance of interactions between primary and at 
least one secondary outcome (e.g. interaction for primary outcome 
significant, but at least one secondary outcome had non-significant 
interaction, or vice versa)** 
13/39 (33) 
*This data summary is limited to the subset of trials which presented interaction results for the 
primary outcome  
**These data summaries are limited to the subset of trials which presented interaction results for 
both the primary and at least some secondary outcomes 
 
 
 
  
Table 5 – Analysis approach 
 Trials (n=100) 
Analysis approach for primary outcome  
     Factorial 51 (51) 
     Multi-arm 23 (23) 
     Chosen based on results from an interaction test (two-stage approach) 18 (18) 
     Both factorial and multi-arm analyses presented, unclear which is primary 5 (5) 
     Unclear 3 (3) 
Analysis results presented from:  
     Factorial analysis only 49 (49) 
     Multi-arm analysis only 22 (22) 
     Both sets 26 (26) 
     Unclear which set presented 3 (3) 
Method of analysis reported in abstract  
     Factorial 46 (46) 
     Multi-arm 25 (25) 
     Both methods 5 (5) 
     Unclear 24 (24) 
Factorial analysis adjusted for other factor  
     Yes 52/75 (69) 
     No 14/75 (19) 
     Unclear 9/75 (12) 
Factorial  analysis appropriately conducted (did not include interaction term)  
     Yes 44/75 (59) 
     No 10/75 (13) 
     Unclear 21/75 (28) 
Multi-arm analysis adjusted for multiple testing  
     Yes 11/48 (23) 
     No 36/48 (75) 
     Unclear 1/48 (2) 
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